🌍·20h agoIndustry
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Publisher
E
Eli Lilly
US
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investor.lilly.com
Leave the platform to read the original full article on the publisher site.
Source: Eli Lilly
Scope: Industry
Related coverage
More related coverage
Bristol Myers Squibb (Global)·8h ago
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Shionogi (IR News)·11h ago
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Us2.ai·11h ago
Apr 2, 2026How Us2.ai and Merge Are Bringing AI Echo Directly Into Clinical WorkflowsRepresentatives from Us2.ai and Merge sat down with the Cardiac Wire Show to discuss their new integration and what it means for the echo techs and cardiologists who use it everyday. Together, the two...
Chugai Pharmaceutical·12h ago
Lilly’s Announcement Regarding Oral GLP-1 Foundayo™ (Orforglipron)
TOKYO, April 2, 2026 -- Chugai Pharmaceutical Co., Ltd. (hereafter “Chugai”, TOKYO: 4519) announced...